AMSBIO has announced the launch of the 96-Well CometChip® System - a high-throughput platform developed to simultaneously treat and measure DNA damage induced by different treatments, or among different cell types on a single slide using the Comet assay.
DNA damaging agents can promote aging, disease and cancer and are widespread in the environment as well as being produced within human cells as normal cellular metabolites. The ability to quantify DNA damage responses is consequently critical to researchers in public health, pharmaceutical or clinical labs.
The CometChip® is based upon the well-established single cell gel electrophoresis “Comet Assay”, which estimates the level of DNA damage by evaluating the extent of DNA migration through a matrix in an electrical field. The type of damage measured by this assay includes abasic sites, crosslinks, and strand breaks.
The Comet Assay has been available in 96-well format, the new CometChip® extends the productivity of...